Argatra

Argatra Uses, Dosage, Side Effects, Food Interaction and all others data.

Argatra is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatra is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.

Argatra is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatra is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatra does not require the co-factor antithrombin III for antithrombotic activity. Argatra exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatra is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatra has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein).Argatra is capable of inhibiting the action of both free and clot-associated thrombin.

Argatra
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Argatra
Availability	Prescription only
Generic	Argatroban
Argatroban Other Names	Argatroban
Related Drugs	warfarin, Coumadin, heparin, alteplase, Jantoven, streptokinase
Type
Formula	C₂₃H₃₆N₆O₅S
Weight	Average: 508.64 Monoisotopic: 508.246789457
Protein binding	54%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Austria, Germany, Slovenia, Switzerland
Last Updated:	September 19, 2023 at 7:00 am

Uses

Argatra is a synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use.

Argatra is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.

Argatra is also used to associated treatment for these conditions: Thrombotic events

How Argatra works

Argatra exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.

Toxicity

Excessive bleeding

Food Interaction

Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of argatroban; however, the evidence is conflicting.
Exercise caution with St. John's Wort.